L3VLUP
ProSign in

PTGX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PTGXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PTGX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterPTGXLLY
Q3 20201 holders, $54m33 holders, $14.1bn
Q4 20202 holders, $60m29 holders, $17.3bn
Q1 20212 holders, $87m24 holders, $23.0bn
Q2 20212 holders, $156m24 holders, $27.8bn
Q3 20214 holders, $130m31 holders, $29.9bn
Q4 20214 holders, $169m31 holders, $34.7bn
Q1 20223 holders, $110m24 holders, $35.3bn
Q2 20225 holders, $67m33 holders, $42.7bn
Q3 20223 holders, $53m31 holders, $43.4bn
Q4 20225 holders, $52m31 holders, $46.6bn
Q1 20234 holders, $116m33 holders, $44.3bn
Q2 20235 holders, $171m37 holders, $59.6bn
Q3 20232 holders, $109m44 holders, $67.6bn
Q4 20232 holders, $191m45 holders, $73.6bn
Q1 20245 holders, $248m41 holders, $95.3bn
Q2 20243 holders, $262m43 holders, $110bn
Q3 20243 holders, $286m45 holders, $107bn
Q4 20244 holders, $253m46 holders, $93.9bn
Q1 20254 holders, $354m42 holders, $98.4bn
Q2 20255 holders, $425m43 holders, $93.2bn
Q3 20258 holders, $790m39 holders, $86.7bn
Q4 202510 holders, $1.3bn41 holders, $123bn
Q1 20269 holders, $1.8bn39 holders, $106bn
Q2 20267 holders, $1.9bn44 holders, $132bn
PTGX

Protagonist Therapeutics Inc

Holders
5
Reported value
$425m
Buyers
4
Sellers
1

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only PTGX (2)

Farallon Capital Management LLC, Winton Group Ltd

Only LLY (40)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →